Abstract：
During treatment with bisphosphonates (peroral or intravenous), there is a risk of osteonecrosis, \"medication-related osteonecrosis of the jaw\" (MRONJ), as a direct consequence of oral surgery or due to chronic infections such as periodontitis or peri-implantitis, particularly with high-dose medication in malignant patients. Necrosis of the jawbone has also been described with oral bisphosphonates in osteoporosis.
摘要：
在双膦酸盐治疗期间（口服或静脉注射），有骨坏死的风险,“药物相关性颌骨坏死”（MRONJ），作为口腔手术的直接后果或由于牙周炎或种植体周围炎等慢性感染，特别是在恶性患者中使用高剂量药物。在骨质疏松症中，口服双膦酸盐也已描述了颌骨坏死。
